Johnson & Johnson today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020.
They expect to initiate human clinical studies at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021.
The company said its goal was to create 1 billion doses of the vaccine, a scale-up made possible by a partnership with the Biomedical Advanced Research and Development Authority (BARDA).
Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said, “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible. As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic.”
- COVID-19 Antibody Therapy: GigaGen Initiates Development of rCIG
- Ebola in the DRC: ‘Outbreak would appear to be coming under control’
- Italy COVID-19 case top 100,000
- Venezuela reports 1st COVID-19 deaths, China to send a contingent of specialists
- New Orleans COVID-19 cases near 1500, City launches PPE drive
- Jamaica reports two additional COVID-19 cases, both with travel history to New York